Filing Flows › 4D Molecular Therapeutics (FDMT) › Q2 2025
4D Molecular Therapeutics (FDMT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
4D Molecular Therapeutics (FDMT) reported revenue of $15K for the second quarter 2025 (Q2 2025), +200% from a year earlier and +7% from the quarter before.
4D Molecular Therapeutics, Q2 2025: revenue $15K (+200% year over year), net loss $54.7M, operating cash flow −$43.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15K | +7% | +200% |
| Operating profit | −$59.5M | — | — |
| Net earnings | −$54.7M | — | — |
| Operating cash flow | −$43.4M | — | — |
What changed
Revenue was $15K in Q2 2025, up 200% year over year and up 7% from the previous quarter.
Operating costs exceeded revenue by $59.5M, an operating margin of -396373.3%. Total costs grew 40% against revenue growth of 200%. The fastest-growing cost line was Research & development (+51%). The quarter ended with a net loss of $54.7M, wider than the previous quarter's $48.0M loss.
Operating cash flow was −$43.4M. Non-cash charges added back $1.2M of depreciation and amortization and $5.0M of share-based compensation. Working capital and other items added $5.2M. Capital expenditures of $66K exceeded it, leaving free cash flow of −$43.4M.
Questions
What was 4D Molecular Therapeutics' revenue in the second quarter 2025?
4D Molecular Therapeutics (FDMT) reported revenue of $15K for the second quarter 2025 (Q2 2025), +200% from a year earlier and +7% from the quarter before.